Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00665353 · ClinicalTrials.gov registry record · Phase 2
Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance
A Phase 2 study of HIV-1 and Hepatitis C Co-Infection, sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
- 8
- Study locations
NCT00665353 is a Phase 2 study of HIV-1 and Hepatitis C Co-Infection that has completed, run by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections. The registered enrollment target is 19 participants. The trial reports 8 study locations across 6 states.
The verdict
NCT00665353, a Phase 2 study of HIV-1 and Hepatitis C Co-Infection, has completed, sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
- 8
- Study locations
Study Summary
Insulin resistance is common in people coinfected with HIV and Hepatitis C virus (HCV) and is associated with poor responses to treatment for HCV. Pioglitazone is an FDA-approved medication for the treatment of type 2 diabetes. It works by increasing the body's sensitivity to insulin. The purpose of this study is to determine whether treatment with pioglitazone prior to HCV treatment with peginterferon and ribavirin is safe and effective in improving the treatment outcome in insulin-resistant, HIV/HCV-coinfected people for whom previous treatment with peginterferon and ribavirin was unsuccessful.
Conditions Studied
Interventions
- DRUG pioglitazone
- DRUG peginterferon
- DRUG ribavirin
Study Locations (8)
New York
- Cornell CRS (7804) - New York
- NY Univ. HIV/AIDS CRS (401) - New York
- AIDS Care CRS (1108) - Rochester
California
- Ucsf Aids Crs (801) - San Francisco
Illinois
- Northwestern University CRS (2701) - Chicago
New Jersey
- New Jersey Medical School-Adult Clinical Research Ctr. CRS (31477) - Newark
Ohio
- Metro Health CRS (2503) - Cleveland
Virginia
- Virginia Commonwealth Univ. Medical Ctr. CRS (31475) - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2009-03 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00665353
The ClinicalTrials.gov registry entry for NCT00665353 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV-1 and Hepatitis C Co-Infection appearing as the primary indexed condition, and to 3 interventions - of which pioglitazone is the first listed.
NCT00665353 reports 8 study locations spanning 6 distinct geographic areas - top geographies include New York, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT00665353 about?
NCT00665353 is a clinical study titled "Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance". Insulin resistance is common in people coinfected with HIV and Hepatitis C virus (HCV) and is associated with poor responses to treatment for HCV. Pioglitazone is an FDA-approved medication for the treatment of type 2 diabetes. It works by increasing the body's sensitivity to insulin. The purpose of...
What is the current status of trial NCT00665353?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2009-03. Estimated completion is 2011-12.
What conditions does trial NCT00665353 study?
This clinical trial studies the following conditions: HIV-1 and Hepatitis C Co-Infection.
What interventions are being tested in trial NCT00665353?
The interventions under investigation include: pioglitazone (DRUG), peginterferon (DRUG), ribavirin (DRUG).
Who is sponsoring clinical trial NCT00665353?
This trial is sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, which has 45 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00665353 being conducted?
This trial has 8 study locations across California, Illinois, New Jersey, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.